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Measuring Acceptable Treatment Failure Rates
for Community-Acquired Pneumonia: Potential for Reducing
Duration of Treatment and Antimicrobial Resistance
Keith S. Kaye, MD, MPH; Anthony D. Harris, MD, MPH; Jay R. McDonald, MD; Larry J. Strausbaugh, MD;
Eli Perencevich, MD, MS; for the Infectious Diseases Society of America Emerging Infections Network

objective. This study was designed to establish the rates of treatment failure for community-acquired pneumonia that are acceptable
to knowledgeable and experienced physicians, in order to facilitate the interpretation of existing studies and the design of new studies
aimed at optimizing the duration of antibiotic therapy. Reducing the duration of antibiotic therapy is one strategy for reducing antibiotic
exposure and thereby minimizing the potential for the emergence of antimicrobial resistance.
design. Survey soliciting the acceptable failure rate for treatment given to an adult patient with uncomplicated community-acquired
pneumonia treated with standard-of-care therapy in the outpatient setting. Analysis was performed using a modification of established
methods of contingent valuation analysis.
participants. Six hundred eighty infectious diseases physicians in North America who were also members of the Emerging Infections
Network of the Infectious Diseases Society of America.
results. Three hundred seventy-five (55.1%) of 680 physicians responded to the survey. The median acceptable failure rate for treatment
was 13.5%. Five hundred ten respondents (75.0%) found a failure rate of 7.3% acceptable, and 170 respondents (25.0%) found a failure
rate of 19.8% acceptable.
conclusions. This study identified the failure rates for treatment of community-acquired pneumonia that were acceptable to infectious
disease physicians. This range of acceptable treatment failure rates may facilitate the design of studies aimed at optimizing the duration of
antimicrobial therapy for community-acquired pneumonia.
Infect Control Hosp Epidemiol 2008; 29:137-142

Community-acquired pneumonia is one of the most commonly treated infections in the United States. It is responsible
for 4.5 million outpatient physician visits annually in the
United States, and the total cost of care is $8.4 billion, 8%
of which is spent on antibiotics.1 Despite the frequency with
which this infection occurs, the optimal duration of antibiotic
therapy has not been well established in clinical trials. Although some guidelines suggest that selected patients with
community-acquired pneumonia may be treated with antibiotics for as little as 5 days, most patients are treated for 710 days or longer.2 Uncertainty about the optimal duration
leads many physicians to prescribe unnecessarily long courses
of antibiotic therapy to patients with community-acquired
pneumonia. Recent clinical trials have begun to evaluate
shorter courses of treatment.3-5
Several authors have proposed that a reduction in the du-

ration of antibiotic therapy may result in a decrease in the
emergence and spread of antimicrobial resistance.6-8 In Streptococcus pneumoniae, the emergence and spread of resistance
to penicillin, cephalosporins, and most recently, fluoroquinolones, have been linked to levels of antibiotic use, both in
individuals and in communities.9-11 In addition, shorter durations of treatment for community-acquired pneumonia are
associated with improved patient compliance wit therapy,4,
12,13
lower drug costs,14 fewer adverse drug-related events,15
improved patient satisfaction, and patient perception of
greater treatment efficacy.16
Studies of therapy for community-acquired pneumonia
typically use treatment failure as an endpoint and rarely examine the emergence and spread of antimicrobial resistance,
cost, patient satisfaction, and/or compliance. Future investigations of shorter durations of therapy for community-ac-
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quired pneumonia would benefit from a clear understanding
of the treatment failure rates that are acceptable to knowledgeable, experienced physicians. To our knowledge, no prior
study has attempted to identify acceptable treatment failure
rates for this common infection. In a survey of infectious
diseases physicians who were members of the Infectious Diseases Society of America’s Emerging Infections Network, we
sought to establish what failure rate for treatment given to
patients with mild to moderate community-acquired pneumonia would be acceptable to infectious diseases physicians.

me th ods
Pilot Study
We performed a pilot study to develop a range of treatment
failure rates. In the pilot study, we asked 55 infectious diseases
physicians to estimate an acceptable failure rate for treatment
given to a patient with uncomplicated community-acquired
pneumonia who met the criteria for outpatient treatment.
Approximately half of the respondents received the question
in an open-ended format; the other half received a multiplechoice question that provided a range of rates as response
options. We defined treatment failure as “the persistence of
symptoms after the first week following the office visit, necessitating hospitalization related to persistent and/or worsening pneumonia.” We used the results to determine the
contingent valuation choices (ie, the possible acceptable failure rates) to be offered in the study questionnaire.
Study Subjects
The Infectious Diseases Society of America’s Emerging Infections Network includes infectious diseases physicians who
belong to either the Infectious Diseases Society of America
or the Pediatric Infectious Diseases Society; these physicians
regularly engage in clinical activity and participate in network
activities. Ninety-five percent of Emerging Infections Network members practice in North America. This survey targeted all 680 Emerging Infections Network members who
treat adult patients in North America.
Questionnaire
In May 2003, the Emerging Infections Network distributed
the survey via facsimile and e-mail to 680 physicians. Subjects
who did not respond to the first survey received a second
facsimile 2 weeks later, and a third 4 weeks later. A total of
300 respondents were anticipated on the basis of response
rates to previous surveys conducted in this network.17-19
The survey included a 1-page introduction and a casebased questionnaire entitled “Failure Rates for Treatment of
Community-acquired Pneumonia Patients” (Appendix, Figure). The questionnaire described a 35-year-old patient with
uncomplicated community-acquired pneumonia who received standard-of-care oral antibiotic therapy in the out-

patient setting. The definition of treatment failure was the
same as the definition used in the pilot study. The physicians
surveyed were asked, “Given the standard treatment scenario
described above, do you feel that the treatment failure rate
listed below would be acceptable (i.e. is the rate listed below
less than or equal to a reasonable estimate of the percent of
patients that you would expect to fail appropriate therapy)?”
A single failure rate was provided, with check boxes marked
“yes” and “no” for the physician’s response. The specific failure rates that were sent to the physicians being surveyed were
based on the results of the pilot study. During the pilot study,
physicians who answered the open-ended question reported
a median acceptable failure rate of 5.0% (range, 0.2%-20%),
and those who answered the multiple-choice question reported a median acceptable failure rate between 2% and 5%
(range, 0.1%-10%). Therefore, the following 10 choices of
acceptable failure rates were distributed to the physicians in
the study questionnaire: 0.1%, 1%, 2%, 3%, 5%, 7%, 10%,
15%, 20%, and 30%. Each Emerging Infections Network
member practicing in North America received a questionnaire
that included 1 of these choices, which were randomly distributed on a regional basis.
This approach to eliciting the respondent’s willingness to
accept certain rates of treatment failure is closely related to
the contingent valuation methodology used in studies of willingness to pay or willingness to accept payment.20 The median
value for the acceptable rate of treatment failure is the summary measurement of the willingness of the population of
respondents to accept the outcome. The “take it or leave it”
approach (ie, offering respondents a single failure rate) described above was used to minimize the potential for framing
effects and anchoring biases (ie, the sensitivity of subject responses to opening bids and the phrasing of questions), which
can occur when open-ended questions are used to elicit preferences in contingent valuation analysis.

table 1. Geographic Distribution of Respondents in Regions Delineated by the Centers for
Disease Control and Prevention
Region
New England
Mid-Atlantic
East North Central
West North Central
South Atlantic
East South Central
West South Central
Mountain
Pacific
US Territory
Canada
Total

No. of
respondents
29
58
50
22
80
13
35
23
59
2
4
375

acceptable treatment failure rates for cap

table 2. Proportions of Infectious Diseases Physicians Who Accepted Specified
Failure Rates for the Treatment of Community-Acquired Pneumonia
Failure rate
specified, %
0.1
1
2
3
5
7
10
15
20
30
Total

Proportion (%)
of respondents
who accepted
29/30 (96.7)
31/34 (91.2)
35/38 (92.1)
36/41 (87.8)
25/32 (78.1)
33/40 (82.5)
17/31 (54.8)
9/30 (30.0)
7/39 (18.0)
7/54 (13.0)
229/369

Statistical analysis
Statistical analyses were performed using SAS, version 8.2
(SAS Institute), and Excel 2000 (Microsoft). For each failure
rate presented to the subjects, the proportion of respondents
who found the rate acceptable was calculated. The distribution of the values of acceptable failure rates was examined,
and the median and interquartile ranges were determined.
The relationship between the willingness to accept a rate and
the rate offered to the subject in the questionnaire was evaluated by use of logistic regression. In addition, bivariable and
multivariable logistic regression were used to evaluate
whether the subjects’ number of years in practice might have
influenced their willingness to accept a certain rate of treatment failure.

139

In the bivariable logistic regression model, with failure rate
as the predictor for the binary outcome “accepted” (ie, the
failure rate was acceptable) or “not accepted” (ie, the failure
rate was not acceptable), the odds that a respondent would
find a proposed failure rate acceptable decreased by 0.84 for
each 1% increase in the proposed failure rate (95% confidence
interval [CI], 0.81-0.87; P ! .001). Thus, if the failure rate
presented in the questionnaire increased from 1% to 2%, the
odds that respondents would accept this higher failure rate
would fall by a factor of 0.84. Similarly, if the failure rate
increased from 5% to 10%, the odds that the 10% rate would
be identified as acceptable (relative to the 5% rate) would
fall by a factor of 0.84 (ie, 0.42).5
Figure 1 shows a fitted logistic curve that illustrates the
proportion of respondents who were willing to accept a certain failure rate across the range of proposed failure rates.
The estimated median failure rate was 13.5%. Thus, if all
subjects were presented with a proposed failure rate of 13.5%,
half of them would have been expected to accept that failure
rate. Three-quarters of all subjects would have accepted a
failure rate of 7.3%, and one-quarter would have accepted a
failure rate of 19.8%.
In a logistic regression model adjusting for the effect of
years in practice, there was no change in the odds ratio (OR)
for likelihood to accept a certain failure rate. The number of
years in practice was not a significant independent predictor
of whether a respondent would accept a given failure rate
(OR, 1.02 [95% CI, 0.99-1.06]; P p .16).

discussion
This study reports physicians’ judgments about acceptable
failure rates for treatment administered for uncomplicated
community-acquired pneumonia in an otherwise healthy 35-

res ults
Of 680 physicians surveyed, 375 (55.1%) responded to the
survey. A total of 6 respondents failed to provide interpretable
data and their questionnaires were excluded, which meant
that responses from 369 infectious disease physicians were
available for analysis. Three hundred sixty-three subjects were
from the United States, 4 subjects were from Canada, and 2
were from a US territory. Subjects in the United States came
from all regions of the country (Table 1). The mean duration
of clinical practice (ⳲSD) among respondents was 16.2 Ⳳ
9.0 years (range, 3 months–41 years).
There was a mean of 36.9 respondents for each numerical
failure rate option, with a minimum of 30 and a maximum
of 54 respondents for each option (Table 2). In general, the
number of respondents who identified a particular failure
rate as acceptable declined as the proposed failure rate increased. Twenty-nine (96.7%) of 30 respondents found a failure rate of 0.1% acceptable, whereas only 7 (13.0%) of 54
respondents found a failure rate of 30% acceptable (Table 2).

figure 1. Relationship between the treatment failure rate given
on the survey and the percentage of respondents willing to accept
that failure rate. Diamonds, 30-54 subjects. Line, fitted curve that
uses all data describing the expected percentage willing to accept
each failure rate.
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year-old treated in the outpatient setting. The median acceptable treatment failure rate reported in our study, 13.5%,
is similar to failure rates reported in recent clinical trials
evaluating therapy for community-acquired pneumonia. In
a systematic review of prospective, randomized clinical trials
of therapy involving adult patients with community-acquired
pneumonia from 1990 to 1997, a total of 16 trials with 33
treatment arms had a median failure rate of 15.5% (range,
0%-34%).21
Our results will facilitate the design of future clinical trials
of treatment of community-acquired pneumonia. Antimicrobial therapy of long duration might improve therapeutic
efficacy, but may also increase the emergence and spread of
antimicrobial resistance, as well as increase costs, the incidence of adverse events, and rates of noncompliance with
therapy; it may also decrease patient satisfaction and perceived treatment efficacy. Therefore, a rational target for treatment efficacy is needed. Our results suggest that a treatment
failure rate of 13.5% or less for uncomplicated communityacquired pneumonia is acceptable to at least 50% of physician
experts. Thus, investigators might choose to shorten the duration of therapy for a given antibiotic regimen, as long as
failure rates do not exceed 13.5%.
Only a few published studies have compared the efficacy
of using different durations of therapy involving the same
drug for the treatment of community-acquired pneumonia.
Recent studies have reported similar rates of treatment failure
among hospitalized patients who received different durations
of azithromycin therapy for the treatment of atypical pneumonia5 and among children who received different durations
of amoxicillin therapy for treatment of nonsevere community-acquired pneumonia.4 Dunbar et al.3 recently reported
the results of a study involving adults with mild to severe
community-acquired pneumonia. A total of 528 patients were
randomized to receive either levofloxacin therapy for 5 days
(750 mg per day) or levofloxacin therapy for 10 days (500
mg per day). At a follow-up visit 7-14 days after the initiation
of treatment, similar rates of clinical failure were observed in
the 5-day group and the 10-day group (7.6% vs 8.9%).3
There were limitations to this study. The response rate to
the survey was 55.1%. This response rate is similar to other
published surveys and questionnaires distributed by the
Emerging Infections Network, and the percentage of respondents was consistent between regions of North America.17-19
It is unlikely that nonparticipation would be associated with
different preferences with respect to acceptable treatment failure rates. Additionally, the survey included only 1 scenario,
that of an otherwise healthy 35-year-old man. Our estimate
of an acceptable treatment failure rate should not be extrapolated beyond such a clinical situation. Patient perceptions
were not measured, and decisions about treatment are often

shared between physician and patient.22 Our findings provide
new information regarding physicians’ perceptions of acceptable failure rates, which is an important step in developing effective shared decision-making models. Future studies might focus on acceptable failure rate thresholds as
reported by patients. Finally, only infectious diseases specialists were surveyed. Additional studies including the opinions of different specialists would be of interest.
The questionnaire methodology, which used an approach
similar to economic contingent valuation, is a strength of this
study. This approach has been used to generate monetary
values for abstract quantities, such as water quality, to evaluate
preferences for health products,23-27 to evaluate societal preferences for health states,28 and to determine acceptable rates
of treatment failure for diabetic foot osteomyelitis.19 The “take
it or leave it” strategy that we used may better approximate
real-life decision making,29 and it may be less prone to framing and anchoring biases,19,20,30 compared with open-ended
strategies.
Estimates of the treatment failure rates that are acceptable
to knowledgeable and experienced physicians can be used to
establish targets for therapeutic efficacy in the design of studies that aim to reduce excess antibiotic use. Decreasing overall
antibiotic exposure will likely slow the emergence and spread
of antimicrobial resistance, reduce medical costs and the incidence of adverse events, and improve patient compliance
with antibiotic therapy. The estimate of an acceptable treatment failure rate for community-acquired pneumonia reported in this study provides a formalized frame of reference
for both the interpretation and design of clinical trials for
treatment of mild to moderate community-acquired pneumonia. Ongoing studies of acceptable treatment failure rates
for community-acquired pneumonia as well as other infectious diseases will help guide the implementation of new
methods of antibiotic therapy, such as short-course therapy,
while also helping to improve communication and facilitate
shared decision making between physicians and patients.
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